In particular, FLT3 is recognized as a major target in the treatment of AML, and agents specifically designed to target this receptor, including AC220 [16] and MLN518 [17], have been shown to induce prolongation of the QT interval in clinical trials, as has the multikinase inhibitor sorafenib [18]. Here, FLT3 is linked to acute myeloid leukemia.